Conclusions
death, cancer/gastrooesophageal junction cancer
This post hoc analysis showed pembrolizumab monotherapy was associated with numerically improved overall survival and a favourable tolerability profile versus chemotherapy in Asians with programmed death ligand 1–positive advanced gastric cancer/gastrooesophageal junction cancer.This study is registered with Subgroup analysis of patients enrolled in Asia in the KEYNOTE-062 study showed first-line pembrolizumab versus chemotherapy improved overall survival and had a favourable tolerability profile in programmed death ligand 1–positive advanced gastric cancer/gastrooesophageal junction cancer.